June 18, 2020 / 5:08 AM / a month ago

BRIEF-GenKyotex Provides New Data From PBC Phase 2 Trial Of Setanaxib

June 18 (Reuters) - GENKYOTEX SA:

* GENKYOTEX PROVIDES NEW CLINICAL DATA FROM THE PBC PHASE 2 TRIAL PROVIDING FURTHER EVIDENCE OF THE ANTI-FIBROTIC ACTIVITY OF SETANAXIB

* SETANAXIB IMPROVED MARKERS OF COLLAGEN TURNOVER INDICATING REDUCED COLLAGEN SYNTHESIS AND ENHANCED COLLAGEN DEGRADATION IN PATIENTS WITH ADVANCED LIVER FIBROSIS

* THESE RESULTS PROVIDE FURTHER MECHANISTIC INSIGHTS FOR ANTI-FIBROTIC ACTIVITY OF SETANAXIB AND EXPLAIN RAPID REDUCTION IN LIVER STIFFNESS ALREADY REPORTED IN THESE HIGH-RISK PATIENTS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below